Rep. April McClain Delaney Sells Bio-Techne Corp Stock

Bio-Techne (TECH), a $7.5B life sciences reagents and diagnostics company, has lagged the market over 52 weeks and is down 18% YTD. Shares fell 16.4% on May 6 after weaker-than-expected Q3 2026 results: revenue $311.4M (-2% YoY) and adjusted EPS $0.53. Analysts expect FY EPS $1.69 (-1.2% YoY); consensus is “Moderate Buy” (9 Strong Buy, 5 Hold). Wells Fargo cut its price target to $62 (Overweight). Mean target $63.75; high $80.

Bio-Techne reported Q3 2026 earnings and revenue below analyst expectations, with an adjusted EPS of $0.53 against a forecasted $0.54, and revenue of $311.4 million against $316.12 million. This underperformance led to a 10.18% drop in pre-market trading. The company cited operational challenges, timing-related headwinds, and softness in emerging biotech spending, but remains optimistic about future growth driven by strategic initiatives in spatial biology, proteomic analysis, and AI integration.

Bio-Techne reported a 2% year-over-year decline in net sales but an increase in net income and EPS for its fiscal third quarter 2026. Despite softer demand, the company affirmed its quarterly cash dividend, indicating a focus on cost discipline and shareholder returns. This suggests Bio-Techne has financial flexibility to invest while rewarding shareholders, although prolonged market weakness remains a risk.

Principal Financial Group Inc. significantly increased its stake in Bio-Techne Corp by 316.7% in the fourth quarter of the prior fiscal year, holding 703,477 shares valued at $41.37 million. This move is part of a larger trend of institutional buying, with hedge funds and asset managers now owning 98.95% of Bio-Techne's stock. Despite analysts holding a "Moderate Buy" rating with an average $66.77 price target, Bio-Techne recently missed its earnings and revenue estimates for the quarter and announced a quarterly dividend of $0.08 per share.

Bio-Techne Corporation shares fell 5.9% after three major Wall Street firms collectively cut their price targets by an average of 13.3%, citing concerns about the biotechnology firm’s near-term prospects. Citigroup, Wells Fargo, and Evercore ISI Group all adjusted their targets, signaling increased caution despite two firms maintaining positive ratings. Investors are advised to monitor the company's next quarterly results for potential catalysts or further validation of analyst concerns.

Deutsche Bank has updated its price target for Bio-Techne (TECH) to $66, down from the previous $75, while reaffirming a Buy rating on the stock. This adjustment comes amidst recent company news, including Bio-Techne missing revenue estimates for its fiscal Q3 and reporting lower adjusted earnings. The article also notes other analysts' price target adjustments for Bio-Techne.